US 12,213,962 B2
Drug resistant immunotherapy for treatment of a cancer
Harold Trent Spencer, Marietta, GA (US); Anindya Dasgupta, Anderson, SC (US); and Lawrence S. Lamb, Birmingham, AL (US)
Assigned to Emory University, Atlanta, GA (US); The UAB Research Foundation, Birmingham, AL (US); and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
Filed by Emory University, Atlanta, GA (US); The UAB Research Foundation, Birmingham, AL (US); and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
Filed on Dec. 9, 2019, as Appl. No. 16/708,180.
Application 16/708,180 is a continuation of application No. 16/283,669, filed on Feb. 22, 2019, granted, now 10,543,233.
Application 16/283,669 is a continuation of application No. 14/283,478, filed on May 21, 2014, granted, now 10,322,145, issued on Jun. 18, 2019.
Application 14/283,478 is a continuation of application No. 13/505,098, abandoned, previously published as PCT/US2010/054608, filed on Oct. 29, 2010.
Claims priority of provisional application 61/257,136, filed on Nov. 2, 2009.
Prior Publication US 2020/0323903 A1, Oct. 15, 2020
Int. Cl. A61K 35/17 (2015.01); A61K 31/4188 (2006.01); A61K 31/495 (2006.01); A61K 31/519 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01)
CPC A61K 31/4188 (2013.01) [A61K 31/495 (2013.01); A61K 31/519 (2013.01); A61K 39/4611 (2023.05); A61K 39/4613 (2023.05); A61K 39/4644 (2023.05); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); A61K 35/12 (2013.01); A61K 2035/124 (2013.01); A61K 2239/48 (2023.05); C12N 2510/00 (2013.01)] 14 Claims
 
1. A composition comprising a carrier and isolated natural killer (NK) cells, wherein greater than about 50% of the NK cells express a heterologous polypeptide that confers resistance to a chemotherapy agent, and wherein the NK cells that express the heterologous polypeptide are present in a therapeutically effective amount.